In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma's New Follow-On Strategy

Executive Summary

For all its noise and parties, speeches, and meetings, the 26th annual JP Morgan Healthcare Conference felt more like an indecisive pause than the industry's first step into the new year. Biotech investors see their best exits through M&A, but activity's been unpredictable and less buoyant than expected. But generics and still-impoverished pipelines will force drug companies to make different choices. The quickest solution to pipeline problems is to imitate biotechs by developing or buying biotech products and technologies. These technologies allow Big Pharma to do with biologics what they used to do with small molecules: create fast-followers. Except that there's far more competition this time around.
Advertisement

Related Content

Reimbursement: The New Biopharma Investment Hurdle
Merck's Head-long Leap into Follow-On Biologics
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008
Pharmaceutical Strategic Outlook: The Trouble with Alliances
Genzyme/Isis: Has ENHANCE Dulled Mipomersen's Prospects?
Almirall: Adapting Primary-Care-focused R&D to a Specialist World
Insulin Delivery: Still Waiting to Exhale
Bristol Revs Its R&D Engine: An Interview with Elliott Sigal and Francis Cuss
Pharma's R&D Heartburn Spells Opportunity for GI-Focused Biotechs
Finding a Way Out of Pharma's Dealmaking Dilemma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003069

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel